Shares of Dare Bioscience, Inc. (NASDAQ:DARE) are trading higher on Tuesday as the company is reporting positive interim results from its Phase 3 clinical trial for Ovaprene, a hormone-free contraceptive.



<h2>Dare Bioscience Ovaprene Phase 3 Interim Results</h2>



The recent interim analysis by the independent Data Safety Monitoring Board (DSMB) showed that the trial could continue without modifications, reinforcing Ovaprene’s potential as a meaningful contraceptive alternative.



The DSMB reviewed data from 339 study subjects, contributing 1,789 menstrual cycles of safety data, representing a proportion of the study’s 2,500-cycle target.



The women’s health company said the study’s findings indicated a pregnancy rate of approximately 9% among participants, consistent with prior expectations.



<div>




Read Also:

Bernie Sanders Mocks Trump Drug Price Claim, Says President 'Who Never Lies, Said He Cut Drug Prices By 400-600%'




</div>


<h2>DARE Technical Analysis: Key Levels And Momentum</h2>



From a technical perspective, Dare Bioscience’s stock is currently trading 7.1% above its 20-day simple moving average (SMA) of $2.49, indicating a bullish short-term trend. The Relative Strength Index (RSI) is at 53.06, suggesting that the stock is in a neutral zone, neither overbought nor oversold, which could indicate room for further upside.



<ul>
<li>Key Resistance: $2.75 — This level is significant as it aligns closely with the recent swing high, suggesting potential selling pressure.</li>



<li>Key Support: $2.49 — This level is important as it corresponds to the 20-day SMA, which could act as a floor for the stock.</li>
</ul>



DARE Stock Price Activity: Dare Bioscience shares were up 5.95% at $2.67 at the time of publication on Tuesday, according to Benzinga Pro data.



Photo: PeopleImages.com – Yuri A via Shuttestock

DARE

SBIO

Dare Bioscience, Inc. (NASDAQ:DARE) shares rose 5.95% to $2.67 following positive Phase 3 interim results for Ovaprene, a hormone-free contraceptive. The independent Data Safety Monitoring Board (DSMB) confirmed the trial could proceed without changes, showing a pregnancy rate of approximately 9% among participants. The stock is trading 7.1% above its 20-day SMA of $2.49, indicating a bullish trend, with key resistance at $2.75 and support at $2.49.

benzinga_article

Dare Bioscience

VanEck Biotech ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

iShares US Medical Devices

SPDR S&P Health Equip

iShares Global Healthcare

iShares US Pharma

First Trust NYSE Arca Biotech Index Fd

Health Care Select Sector SPDR

VG Health

SPDR S&P Biotech

Ark Genomic Revolution ETF

iShares Biotechnology ETF

Why Is Nano-Cap Dare Bioscience Stock Trading Higher On Tuesday?